16 Penn Tower
34th and Civic Center Blvd.
Philadelphia, PA 19104

215-349-8140
215-662-7804 fax

Clinical Interests

Genitourinary oncology (testicular, prostate, bladder, and kidney cancers)

Clinical Research Program

Dr. Vaughn's research focuses upon patients with genitourinary cancer, with a special interest in drug development for bladder and prostate cancer. He is Study Chair for E5899, an Eastern Cooperative Oncology Group (ECOG) trial of paclitaxel/gemcitabine in patients with advanced urothelial cancer and renal insufficiency. He is Principal Investigator for a national multi-institutional trial of weekly paclitaxel plus estramustine phosphate in hormone-refractory prostate cancer. He is also PI of an investigator-initiated trial testing this regimen as adjuvant therapy in high-risk prostatectomy patients. He participates in multiple ECOG and industry-sponsored genitourinary cancer clinical trials.

In collaboration with Dr. James Coyne of the Behavioral Science program, Dr. Vaughn is studying men with advanced prostate cancer on androgen ablation therapy with respect to hot flashes, fatigue, and quality-of-life. Dr. Vaughn and others have initiated the Lance Armstrong Foundation-funded Living Well After Cancer program, a clinical and research center for cancer survivors. He leads the Testicular Cancer Survivorship program. Planned research studies will focus upon a) the impact of the late consequences of chemotherapy on quality-of-life and b) detection of subclinical atherosclerosis in testicular cancer survivors.

As chair of the Penn Cancer Clinical Trials Group (PCCTG), a consortium of community oncologists of the Penn Cancer Network, Dr. Vaughn leads this clinical research cooperative group. PCCTG has completed trials in a broad variety of tumor types, resulting in publications and presentations at national meetings.

Selected Publications (2001)

Stein S., Zoltick B., Peacock T., Holroyde C., Haller D., Armstead B., Malkowicz S.B., Vaughn D.J. Phase II trial of toremifene in androgen-independent prostate cancer: a Penn Cancer Clinical Trials Group trial. American Journal of Clinical Oncology 24:283-5, 2001.

Malkowicz S.B., McKenna W.G., Vaughn D.J., Wan X.S., Propert K.J., Rockwell K., Marks S.H.F., Wein A.J., Kennedy A.R. Effects of Bowman-Birk inhibitor concentrate (BBIC) in patients with benign prostatic hypertrophy. The Prostate 48:16-28, 2001.

Sun W-J., Vaughn D.J. Adjuvant chemotherapy for muscle-invasive bladder cancer. Seminars in Urologic Oncology, 19:186-93, 2001.

Vaughn D.J., Malkowicz S.B.: Recent developments in chemotherapy for bladder cancer. Oncology 15:763-775, 2001.

Vaughn D.J., Broome C., Hussain M., Gutheil J., Markowitz A. A phase II trial of weekly paclitaxel in previously treated advanced urothelial cancer. J Clin Oncol, In press.